(SHR-A1403) 药物类型:ADC 适应症:晚期实体瘤 靶点:C-MET 是否上市:临床中 研发公司:恒瑞医药(中国) 说明书:简介(概括) 详细说明书 临床指南 基因与耐药 副作用与并发症 药品百科 临床指南 SHR-A1403相关基因检测 肿瘤组织962基因检测升级版 基于新一代高通量测序(NGS)技术,一次性检测962个肿瘤精准...
exposure and/or ADA incidence were observed for SHR-A1403 with high or low drug-antibody ratio (DAR), which was DAR=5 to 6 and DAR=1, respectively, and therefore prompted selection of an appropriate DAR value (DAR=2) for SHR-A1403 used in preclinical development and clinical trials. 6...